Addario, Van Auken foundations announce 2018 Young Innovators Team Award

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The Bonnie J. Addario Lung Cancer Foundation, in collaboration with the Van Auken Private Foundation, announced the 2018 Young Innovators Team Award to fund and support teams of young investigators conducting innovative research with a potential of delivering meaningful and measurable results in the field of lung cancer.

The 2018 Young Innovators Team Award will provide up to a total of $250,000 to teams of two or more young investigators over two to three years. The awardees must be within five years of their first faculty appointment.

The YITA Scientific Review Committee will evaluate all submissions on the following four main criteria:

  • Out-of-the-box: High-risk, high-impact research that will typically not be selected for federal funding, is creative and has potential for near-term benefit to lung cancer patients

  • Collaborative: Research that fosters collaboration among young researchers who have not worked together in the past, preferably across-institutions

  • Translational: Research with outcomes that can be quickly moved from the lab to the clinic, or from the bench to bedside

  • Multi-Disciplinary: Projects that involve multiple academic disciplines/specializations in their approach to solve a problem in the field of lung cancer

The funding mechanism is designed so that young investigators work together in cross-disciplinary teams. The teams drive the projects with guidance from mentors at their own institution. The 2018 YITA Scientific Review Committee also guides and steers their progress, and makes final decisions on continued funding.

ALCF prefers lung cancer patient-oriented research in the following topic areas (however, the 2018 YITA Scientific Review Committee will evaluate all submissions):

  • Early detection and screening using novel, validated biomarkers

  • Targeting the tumor microenvironment-combination strategies

  • Biomarkers for response to immunotherapies

  • Small Cell Lung Cancer: identifying and targeting specific underlying genomic abnormalities

  • Causative factors in non-smokers

Key Dates

  • May 31, 2018 – RFA announcement

  • May 31, 2018 – Online application submission portal opens

  • July 1, 2018 – Optional pre-application counseling deadline

  • July 15, 2018 – Application submission deadline

  • Aug. 15, 2018 – Peer review round 1October 15, 2018 – Peer review round 2: Top 3-5 applicants present to the Scientific

  • Review Committee/in-person review

  • Oct. 31, 2018 – Award announcements

  • Nov. 1, 2018 – Award start date

  • Nov. 1, 2020 or Nov. 1, 2021 – Award end date (depending on the proposal)

For more information, visit www.lungcancerfoundation.org/yita-2018. The website also has information on the award, guidelines for submission, FAQs and the online submission portal. ALCF will accept online applications during May 31 – July 15, 2018. ALCF and the Van Auken Private Foundation provide funding for this award.

YOU MAY BE INTERESTED IN

On Feb. 19, GRAIL Inc. announced that its pivotal NHS-Galleri trial failed to meet its primary endpoint of reduction in advanced stage cancers. The media and the market reacted as one would expect: GRAIL’s stock price halved the day after the announcement and at least three law firms said that they are conducting investigations in preparation for filing investor suits.
If you listen to GRAIL executives discuss the results of the long-awaited trial of the company’s multicancer detection test, you might be led to conclude that the company’s pivotal NHS-Galleri study had an overwhelmingly positive result.
Undeterred by the negative topline result of its pivotal trial of Galleri, a multicancer detection test, the test’s sponsor, GRAIL, said it’s forging ahead with its plan to get FDA approval and reimbursement from CMS and private insurers.
Philip E. Castle, director of the NCI Division of Cancer Prevention, said he was disappointed to hear that GRAIL’s NHS-Galleri trial did not meet its primary endpoint of reduction in late-stage cancers.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login